D NA extracted from seven enterococci isolated from this patient over a 7 month period (three VSE , two VR E , the VD E and a non-dependent peripheral colony growing on the same plate as the VD E ) demonstrated that they were virtually indistinguishable (data not shown).
O ur observations suggest that the repeated use of vancomycin in this patient resulted in progression of the same enterococcal strain from vancomycin susceptibility, first to vancomycin resistance and subsequently to vancomycin dependence, i.e. acquisition by a vancomycin-susceptible strain of a vancomycin resistance determinant, rather than acquisition of a second vancomycin-resistant strain. Moreover, the antibiotic failed to eradicate the organism, but selected a genotypic expression that conferred a survival advantage, a development that may eventually pose a threat to the wellbeing of the host. O n the other hand, the phenomenon of vancomycin dependence is unlikely to be anything more than the facilitation of growth of a mutant isolate in the presence of the antibiotic. There is, to date, no evidence that vancomycin dependence represents any more of a concern than vancomycin resistance, with the possible exception that it might lead to the failure to detect VD E on normal culture media. In the case reported here, however, this would have been unlikely as repeated subculture of the VD E consistently resulted in growth of resistant colonies distant from the vancomycin disc/strip; these colonies were presumably revertants from dependence and have been described previously.
1 R ather, it seems that mutation to vancomycin dependence does indeed represent an 'evolutionary dead-end' 4 because it is lethal in the absence of the antibiotic.
There are, however, other concerns that we consider to be of greater importance than the 'discovery' of vancomycin dependence. This department has recently isolated VR E from 17 patients, six (35% ) of whom were co-infected with MR SA . G iven the on-going and unavoidable use of vancomycin as therapy of patients with invasive infections caused by MR SA , it was not surprising that the incidence of isolating VR E has risen. Not only does this epidemic constitute an immediate health risk, owing to the difficulty in effectively treating patients infected with these organisms, but, looking to the future, the co-existence of VR E and MR SA in the same patient poses the greatest threat yet of the in-vivo transfer of genetic material encoding vancomycin resistance to MR SA , with the advent of a highly virulent and currently untreatable pathogen-a genuine 'superbug'.
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Changes in antimicrobial resistance of enterococci isolated in Greece

epartm ent of M icrobiology, A H E PA University H ospital, T hessalonik i, G reece
Sir, E nterococci have emerged as important nosocomial pathogens, particularly in hospitals where cephalosporins are used at large. For serious enterococcal infections, the combination of a cell wall active antibiotic (such as ampicillin or vancomycin) plus an aminoglycoside remains the most suitable therapeutic choice. H owever, such infections become difficult to treat when resistance to these emerges. 1 We have previously reported trends in susceptibility to these antimicrobials among enterococci isolated during 1993-94 from clinical infections in northern G reece. 2 In that study, relatively high rates of antibiotic resistance were detected for all compounds tested and a considerable number of enterococci were found to produce -lactamases.
In the present report, of strains isolated from the same hospital setting during 1996-97, we have estimated changes in susceptibility to antibiotics among enterococcal strains responsible for clinical infections. A total of 151 E nterococcus faecalis and 38 E nterococcus faecium non-repetitive strains were consecutively isolated at A H E PA U niversity H ospital, one of the largest hospitals in northern G reece. Identification to species level was performed using a conventional test scheme, 3 and a microdilution method, with Pasco MIC G ram-positive panels (D ifco Laboratories, D etroit, MI, U SA ), was used to determine their susceptibility to a range of antimicrobials. Susceptibility status was defined according to NCCLS guidelines. 4 Isolates were tested for -lactamase production by the nitrocefin method.
The Table shows rates of resistance to antibiotics commonly used in combination for enterococcal infections. R esistance to ampicillin among E . faecium strains had increased from 68.7% in the period 1993-94 to 81.6% in the present study, while among E . faecalis strains had decreased from 14.0% to 4.0% ( 2 ; Yates corrected; P 0.007). Strains producing -lactamase were not identified in the current study, although in the earlier one 7.1% of the enterococci were -lactamase positive. This fact could partly explain the decreased resistance to penicillins observed among E . faecalis strains. Vancomycin resistance was not detected in the current study, while 7.6% of the strains were resistant to the drug in the earlier study. H owever, in contrast with the observations of vancomycin resistance and -lactamase production, resistance to high levels of aminoglycosides had increased. H igh-level gentamicin resistance which was about 20% for both species, increased to 26.3% for E . faecium and 43.7% for E . faecalis (P 2 10 4 ). Moreover, high-level streptomycin resistance had increased in E . faecium from 40.6% to 63.2% (P 0.04) and in E . faecalis from 21.5% to 62.9% (P 10   5 ). It is of interest that all ten E . faecium strains resistant to high levels of gentamicin exhibited additional resistance to ampicillin as well as to high levels of streptomycin. Furthermore, most of these multi-resistant strains were isolated from patients with chronic underlying diseases and were the definite source of or a significant contributory factor in serious infections such as bacteraemia. The emergence of high-level gentamicin-resistant E . faecium strains exhibiting cross-resistance to ampicillin has been reported in a London hospital. 5 In our study, the simultaneous occurrence of high-level streptomycin resistance is of obvious additional concern because very few therapeutic alternatives remain effective.
Thus, although clusters of strains producing -lactamase or exhibiting resistance to vancomycin seem to have disappeared over the last two years, a further development of intrinsic resistance to penicillins and of high-level aminoglycoside resistance (H LA R ) has occurred in our hospital.
Cross-infection or overuse of antibiotics may have promoted the emergence of ampicillin resistance, that is chromosomal in origin among E . faecium strains. Moreover, the spread of a particular clone may be responsible for the substantial increase in the prevalence of H LA R enterococci during 1996-97. The dissemination of plasmids that encode resistance to high levels of both gentamicin and streptomycin cannot be excluded in some instances. Work is currently in progress to obtain some insight into the clonal variation of the genes conferring H LA R among enterococci. The fact that these bacteria are now more common pathogens in our clinical setting necessitates the continuous evaluation of their antimicrobial susceptibility trends in order to identify significant changes. These observations may be helpful in the formulation and implementation of a hospital antibiotic policy. 
National Committee for Clinical Laboratory Standards. (1993).
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third Edition: Approved Standard M7-A3.
NCCLS, Villanova, PA. Sir, E nterococci are currently amongst the most troublesome hospital pathogens and effective therapy of patients with infective endocarditis (IE ) caused by these bacteria, especially those that are highly resistant to aminoglycosides, is particularly difficult and has not yet been standardized. R ecently, Tripodi et al. 1 reported that treatment with co-trimoxazole, in combination with ciprofloxacin, cured a patient with IE caused by such a strain. This combination has also been shown to be bactericidal in vitro against five of seven strains of E nterococcus faecium and seven of nine of E nterococcus faecalis; the MICs of ciprofloxacin for all of the isolates were 4 mg/L. 2 We describe here a patient with IE caused by a strain of E . faecalis exhibiting high-level resistance to gentamicin who was successfully treated with a regimen comprising cotrimoxazole and ciprofloxacin.
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A 25 year old female patient was admitted to our hospital with a history of pain in multiple joints (for 2 months) and fever (for 1 month). The fever was initially low-grade, but reached a peak of 39°C after a few days and exhibited a continuous or continuous-remittent pattern. O n the basis of serological investigations (an antistreptolysin O (A SO ) titre of 333 Todd units and a streptozyme (A STZ ) titre of 1:200), therapy comprising oral salicylate (150 mg/kg body weight/day) and procaine penicillin G 1.2 mU bd im was commenced. The fever fell slightly, but, after 1 week, a second physician, suspecting IE on the basis of the longstanding fever and pre-existing mitral and aortic valve disease, altered the antibiotic therapy to benzylpenicillin 20 mU /day, administered by the intravenous route, and gentamicin 80 mg tds im. This regimen was given for 1 week, during which time there was no improvement. Four blood cultures, obtained 3 days after discontinuing the antibiotics, were sterile and therapy with iv teicoplanin 400 mg bd for the first 2 days, followed by 200 mg bd on subsequent days, together with gentamicin, was initiated. A fter a further 3 days of treatment with this regimen, the patient complained of increasing malaise and she was transferred to our care for further evaluation.
O n examination, the right ankle, left knee and distal interphalangeal joints were tender. Slight swelling, redness and functional impairment of the knee joint were also noted. E xamination of the heart showed sinus tachycardia, a third heart sound, a grade 2/6 pandiastolic murmur over the aortic area and a grade 3/6 systolic murmur at both E rb's area and the apex which radiated to the axilla. U rinalysis revealed slight proteinuria and microscopic haematuria, while haematological and biochemical investigations showed mild anaemia, a normal leucocyte count, hypoalbuminaemia and mild hypergammaglobulinaemia. No vegetations were identified on a two-dimensional echocardiogram, but moderate mitral and slight aortic regurgitation were present on D oppler echocardiography.
Because of persistent pyrexia, the antibiotic therapy was discontinued and, 3 days later, nine blood cultures were obtained. Six of these yielded a strain of E . faecalis. The susceptibilities of the isolate were determined by the microbroth dilution method according to a protocol issued by the National Committee for Clinical Laboratory Standards (NCCLS); Whilst awaiting the outcome of susceptibility testing, the teicoplanin and gentamicin were recommenced, but, when the results became available, the gentamicin was withdrawn and ciprofloxacin 200 mg bd iv was administered with the teicoplanin. Following 3 days of treatment with this regimen, the fever resolved. H owever, serumcidal studies (with Mueller-H inton broth and an inoculum of 5 10 8 cfu/L) revealed an absence of both trough and peak bactericidal activities. We therefore evaluated various antibiotic combinations (ciprofloxacin and teicoplanin, ciprofloxacin and vancomycin and ciprofloxacin and co-trimoxazole) by the chequerboard method (again with Mueller-H inton broth and an inoculum of 5 10 8 cfu/L). O f the combinations tested, only ciprofloxacin and co-trimoxazole exhibited synergic activity (bactericidal activity at concentrations equivalent to 0.25 MIC of each drug and fractional inhibitory concentration 0.5); the others exhibited indifferent activity. Co-trimoxazole 960 mg bd iv was therefore added to the ciprofloxacin and the teicoplanin discontinued. O n the third day after starting this regimen, the patient's trough and peak serumcidal titres were 1:16 and 1:32 respectively.
